Retinoid therapy : a review of clinical and laboratory research : the proceedings of an international conference held in London, 16-18 May 1983
著者
書誌事項
Retinoid therapy : a review of clinical and laboratory research : the proceedings of an international conference held in London, 16-18 May 1983
MTP Press, c1984
大学図書館所蔵 全4件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
"The symposium was held under the auspices of the ESDR and of Roche Products Limited"--Pref
Includes bibliographical references and index
内容説明・目次
内容説明
The impact of the retinoids in clinical practice has primarily been in dermatology. When Dr Werner Bollag began his basic research and screening programme in the early 1960's, the expectation was that the retinoids would have a major impact on oncology. However, the laboratory and clinical experiences of Bollag and his colleagues in Switzerland, Stuttgen and Orfanos in Germany, led to publications on both etretinates (Tigason) and isotretinoin (Roaccutane) in the years between 1972 and 1976 in the field of dermatology. In fact the first symposium on retinoid research held in Berlin in 1981 was almost entirely dermatological. A year later a retinoid workshop in Iowa was designed to provide a forum for dermatolog- ists from the USA involved in specific protocols investigating oral retinoids. In the UK, research into the retinoids began rather later than in Continental Europe or in the USA, although Tigason was first marketed here. It was felt in late 1982 that as many dermatologists had relatively little experience with these compounds it would be appropriate to hold an International Symposium on retinoid therapy in the UK.
Thus on 16-18 May 1983 in London, 37 speakers from 11 countries addressed an audience of 300, aminly UK, dermatologists. The scientific organizing committee consisted of but two persons Dr William Cunliffe of Leeds General Infirmary, representing the European Society of Dermatolo- gical Research, and myself from Roche Clinical Research. The Symposium was held under the auspices of the ESDR and of Roche Products Limited.
目次
1 The Development of Retinoids in Dermatology.- Section 1: Clinical and Laboratory Studies with Etretinate.- 2 Etretinate and Isotretinoin, Two Retinoids with Different Pharmacokinetic Profiles.- 3 Experience with Etretinate in the UK.- 4 The Treatment of Children with Etretinate.- 5 Austrian Experience with Etretinate.- 6 PUVA-Etretinate Therapy in Chronic Plaque and Palmar Plantar Pustular Psoriasis.- 7 The Use of Tigason (Etretinate) in Darier's Disease.- 8 Etretinate in the Ichthyosiform Erythrodermas.- 9 Lupus Erythematosus and Etretinate.- 10 Etretinate Treatment in Erosive Lichen Planus of the Oral Mucosa.- Section 2: Etretinate - Mechanism of Action.- 11 Overview of Mode of Action of Retinoids.- 12 Effects of Synthetic Retinoids on Human Peripheral Blood Lymphocytes and Polymorphonuclears in Vitro.- 13 Effects of Retinoids on Chondrogenesis and Epidermogenesis in Vitro.- 14 Further Observations on the Pharmacology of Retinoids.- 15 The Effects of Etretinate on Angiogenic Capability and Cytotoxic Activity of Pheripheral Blood Lymphocytes in Psoriasis.- 16 The Effect of Etretinate on Chemotactic Activity of Polymorphonuclear Leukocytes in Various Forms of Psoriasis.- Section 3: Special Examinations with the Retinoids.- 17 Spermatological Examinations in Males Treated with Etretinate.- 18 Effects of Oral Retinoids on Enzyme Activities of Rat Intestinal and Kidney Tubular Epithelium.- Section 4: Retinoids and Neoplasia.- 19 Detection of Precancerous Bronchial Metaplasia in Heavy Smokers and its Regression after Treatment with a Retinoid.- 20 Cutaneous Neoplasia and Etretinate.- 21 Cutaneous Neoplasia and the Retinoids.- Section 5: Isotretinoin - Clinical and Laboratory.- 22 A Dose Response Study of 13-cis-Retinoic Acid Therapy in Cystic Acne.- 23 Isotretinoin in the Treatment of Acne.- 24 The Overall USA Experience of Retinoids in Acne.- Section 6: Isotretinoin - Duration of Remission of Acne.- 25 Relapse Rate of Acne Conglobata after Stopping Isotretinoin.- 26 A Follow-up Study of 13-cis-Retinoic Acid Therapy in Cystic Acne.- Section 7: Isotretinoin - Mechanism of Action.- 27 13-cis-Retinoic Acid in Acne - Mechanism of Action.- 28 Effect of 13-cis-Retinoic Acid and Cyproterone Acetate on Acne Severity, Sebum Excretion Rate, Dermal and Epidermal Lipogenesis, Serum Lipids and Liver Function Tests.- 29 Isotretinoin and Oral Contraceptive Steroids.- Section 8: Comparisons of Isotretinoin with other Drugs in the Treatment of Severe Acne.- 30 Comparison of Isotretinoin and Cyproterone Acetate - a Clinical and Laboratory Study.- 31 A Comparative Study of 13-cis-Retinoic Acid and Erythromycin Therapy in Severe Acne.- 32 Use of Isotretinoin in Severe Cases with Papular Pustular Acne.- Section 9: other uses of Isotretinoin.- 33 The Use of Isotretinoin in Rosacea.- 34 Use of Isotretinoin in the Ichthyoses.- Section 10: New Aspects of Retinoid Therapy.- 35 Response of Psoriatic Arthropathy to Arotinoid (Ro 13-6298): A Pilot Study.- 36 Anti-Inflammatory Effects of the Retinoids.- 37 No Influence of Three Synthetic Retinoids (Ro 10-1670, Ro 4-3780, Ro 13-6298) on Lipoxygenase Activity in Two in Vitro Systems.- 38 The Management of Cystic, Conglobate and Severe Acne Irresponsive to Systemic Antibiotics with Roaccutane.
「Nielsen BookData」 より